Therapeutic blockade of the CXCL12/CXCR4 axis with CXCR4 inhibitors in prostate cancer models reduces Treg infiltration, restores CD8+; cytotoxicity, and suppresses tumor growth, with the strongest effects seen when combined with IL-2 supplementation. This evidence concerns the gene CD8A and prostate cancer.